期刊名称：EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 The European Journal of Medicinal Chemistry publishes studies on all aspects of medicinal chemistry: organic synthesis; biological behavior; pharmacological activity; drug design; QSAR; molecular modeling; drug-receptor interactions; molecular aspects of drug metabolism; prodrug synthesis and drug targeting. The journal accepts papers from any country, European or otherwise, and provides a medium for publication of original papers, laboratory notes, short or preliminary communications, and invited reviews.
Comments and Proposals: Elsevier also publishes books in this area. If you have a suggestion for a book topic or would like to submit a book proposal, please contact us at: chemistry@elsevier.com
Instructions to Authors
European Journal of Medicinal Chemistry
Instructions to authors
1. Aims and scope
The European Journal of Medicinal Chemistry publishes studies on all aspects
of medicinal chemistry, including organic synthesis; biological behaviour;
pharmacological activity; drug design; QSAR; molecular modelling; drugreceptor
interactions; molecular aspects of drug metabolism; prodrug synthesis
and drug targeting. The journal accepts papers from any country, European or
otherwise, and provides a medium for publication of the following articles:
Original papers are full papers describing original research of high
scientific level and timeliness. They are definitive reports on a full study.
Short communications are shorter pieces of work and report limited studies
of the same level as described in original papers.
Preliminary Communications are also limited studies but describe particularly
novel and significant new findings which shall be developed further in
the future.
Laboratory notes are focused on practical aspects. They may deal with an
original synthesis of a series of compounds or with new pharmacological
methods.
Review articles are specially commissioned by the Editors and may embrace
the results of various workers in a given area or may feature recent developments
from the author’s own laboratory. A review that is distinguished by a
novel interpretation or representation of earlier findings is especially
suitable. The Editors welcome inquiries concerning the suitability of a
particular topic for a review article.
In addition, a book review section appears in the journal from time to time.
2. Submission of manuscripts
2.1 General
Manuscripts must be written in English. It is essential to give a fax number and
e-mail address for the corresponding author when submitting a manuscript.
Submission of an article implies that the work described has not been published
previously (except in the form of an abstract or as part of a published lecture or
academic thesis), that it is not under consideration for publication elsewhere,
that its publication is approved by all authors and tacitly or explicitly by the
responsible authorities where the work was carried out, and that, if accepted, it
will not be published elsewhere in the same form, in English or in any other
language, without the written consent of the Publisher.
Manuscripts will be evaluated by the Reading Committee which maintains the
option of requesting that the authors modify their texts. Their originality and
quality are determined by at least two independent referees. To insure a timely
publication process, authors are requested to read the following instructions
carefully and to prepare their manuscript accordingly.
There are no submission fees or page charges for papers published in The
European Journal of Medicinal Chemistry.
Articles and any other material published in The European Journal of
Medicinal Chemistry represent the opinions of the author(s) and should not be
construed to reflect the opinions of the Editor and the Publisher.
2.2 Submission of manuscripts
European Journal of Medicinal Chemistry uses a Web-based online manuscript
submission and review system. Authors must submit their manuscript to one of the
Editors (see below) via the online submission page http://ees.elsevier.com/ ejmech.
Editor-in-Chief
Professor Olivier Lafont, Châtenay-Malabry Cedex, France.
Associate Editors:
Dr Salvatore Guccione, Catania, Italy.
Prof. Antonio Monge-Vega, Pamplona, Spain.
Authors will be guided stepwise through the creation and uploading of the
various files. The system automatically converts source files to a single Adobe
Acrobat PDF version of the article, which is used in the peer-review process.
Please note that even though manuscript source files are converted to PDF at
submission for the review process, these source files are needed for further
processing after acceptance. All correspondence, including notification of the
editor’s decision and requests for revision, takes place by e-mail and via the
author’s home page. A printed copy of the manuscript is not required at any
stage of the process.
Manuscripts should be accompanied by a graphical abstract (submitted as a
separate document) for the contents list and a cover letter outlining the basic
findings of the paper and their significance, as well as the names and contact
details of 4? potential referees.
3. Copyright guidelines
Upon acceptance of an article, authors will be asked to transfer copyright (for
more information on copyright see http://www.elsevier.com/copyright). This
transfer will ensure the widest possible dissemination of information. An e-mail
will be sent to the corresponding author confirming receipt of the manuscript.
A form facilitating transfer of copyright will be provided. If excerpts from
other copyrighted works are included, the author(s) must obtain written
permission from the copyright owners and credit the source(s) in the article.
Elsevier Science has preprinted forms for use by authors in these cases: contact
ES Global Rights Department, P.O. Box 800, Oxford, OX5 1DX, UK; phone:
(+ 44) 1865 843830, fax: (+ 44) 1865 853333, e-mail: permissions@elsevier.com
4. Presentation of manuscript
Manuscripts should be written in good English. Italics are not to be used for
expressions of Latin origin, for example, in vivo, et al., per se. Use decimal
points (not commas); use a space for thousands (10 000 and above).
Ensure that each new paragraph is clearly indicated. Manuscript pages should
be numbered consecutively and organized as follows : Title Page, Main text,
Acknowledgement, References, Figure captions, Tables, Figures and Schemes.
If possible, consult a recent issue of the journal to become familiar with
layout and conventions. For a free online sample copy, please go to www.
sciencedirect.com.
Graphical abstracts: Authors must supply a graphical abstract for inclusion in
the journal’s graphical table of contents. The abstract should summarise the
contents of the paper in a concise, pictorial form designed to capture the attention
of a wide readership. Carefully drawn chemical structures are desired that
serve to illustrate the theme of the paper. Authors may also provide appropriate
text, not exceeding 30 words. The content of the graphical abstract will be typeset
and should be kept within an area of 5 cm by 17 cm. Authors must supply
the graphical abstract separately as an electronic file.
Title page: Provide the following data on the title page (in the order given).
Title. Concise and informative. Avoid abbreviations and formulae where
possible.
Author names and affiliations. Where the family name may be ambiguous
(e.g., a double name), please indicate this clearly. Present the authors?affiliation
addresses (where the actual work was done) below the names. Indicate
all affiliations with a lower-case superscript letter immediately after the
author’s name and in front of the appropriate address. Provide the full postal
address of each affiliation, including the country name, and, if available, the
e-mail address of each author.
Corresponding author. Clearly indicate who is willing to handle correspondence
at all stages of refereeing and publication, also post-publication.
European Journal of Medicinal Chemistry
Instructions to authors
Ensure that telephone and fax numbers (with country and area code)
are provided in addition to the e-mail address and the complete postal
address.
Abstract. A concise and factual abstract of no more than 120 words is
required. The abstract should state briefly the purpose of the research, the
principal results and major conclusions. An abstract is often presented separate
from the article, so it must be able to stand alone.
Keywords. Immediately after the abstract, provide a maximum of 3? keywords,
avoiding general and plural terms and multiple concepts (avoid, for
example, ‘and? ‘of?. Be sparing with abbreviations: only abbreviations
firmly established in the field may be eligible. These keywords will be used
for indexing purposes.
Abbreviations. Define abbreviations that are not standard in this field in a
footnote to be placed on the first page of the article. Such abbreviations that are
unavoidable in the abstract must be defined at their first mention there, as well
as in the footnote. Ensure consistency of abbreviations throughout the article.
Main text: The manuscript should be written as clearly and concisely as possible.
The author is responsible for providing the correct nomenclature which
must be consistent and unambiguous. The use of chemical names for drugs is
preferred. The text should be arranged in the following order: Introduction,
Chemistry, Pharmacology, Results, Discussion, Conclusion and Experimental
protocols. Each section should be clearly marked with a separate, numbered
heading and may be numbered down to the fourth order.
Footnotes should be designated in the text by superscript numbers and listed on
a separate sheet, starting with the title; in tables they should be noted by superscript
letters and placed at the bottom of the page containing the table.
Analytical data should be included for examination by the editor and referees.
However, these data will not be printed if they agree within ?0.4 % with calculated
values, but may be noted as follows: ‘Anal. C14H15NO3 (C, H, N, O)? with the
mentioning under Experimental protocols: ‘Analyses indicated by the symbols
of the elements or functions were within ?0.4 % of the theoretical values?
Instructions regarding GenBank/DNA Sequence Linking: DNA sequences
and GenBank Accesion numbers: Many Elsevier journals cite “gene accession
numbers?in their running text and footnotes. Gene accession numbers refer to
genes or DNA sequences about which further information can be found in the
database at the National Center for Biotechnical Information (NCBI) at the
National Library of Medicine. Elsevier authors wishing to enable other scientists
to use the accession numbers cited in their papers via links to these
sources, should type this information in the following manner: For each and
every accession number cited in an article, authors should type the accession
number in bold, underlined text. Letters in the accession number should
always be capitalised. (See Example 1 below). This combination of letters and
format will enable Elsevier’s typesetters to recognize the relevant texts as
accession numbers and add the required link to GenBank’s sequences.
Example 1: “GenBank accession nos. AI631510, AI631511, AI632198, and
BF223228, a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no. BE675048), and a T-cell lymphoma (GenBank accession no.
AA361117)?
Authors are encouraged to check accession numbers used very carefully. An
error in a letter or number can result in a dead link. In the final version of
the printed article, the accession number text will not appear bold or underlined
(see Example 2 below).
Example 2: “GenBank accession nos. AI631510, AI631511, AI632198, and
BF223228, a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no. BE675048), and a T-cell lymphoma (GenBank accession no.
AA361117)?
In the final version of the electronic copy, the accession number text will be
linked to the appropriate source in the NCBI databases enabling readers to go
directly to that source from the article.
Acknowledgments: Place acknowledgements, including information on grants
received, before the references, in a separate section, and not as a footnote on
the title page.
References: Responsibility for the accuracy of bibliographic citations lies
entirely with the authors. Please ensure that every reference cited in the text is
also present in the reference list (and vice versa). Any references cited in the
abstract must be given in full. Unpublished results and personal communications
should not be in the reference list, but may be mentioned in the text.
Citation of a reference as ‘in press?implies that the item has been accepted for
publication.
Text: Indicate references by number(s) in square brackets in line with the text.
The actual authors can be referred to, but the reference number(s) must always
be given.
Example: ?.. as demonstrated [3,6]. Barnaby and Jones [8] obtained a different
result...?BR>List: Number the references (numbers in square brackets) in the list in the order
in which they appear in the text.
Examples:
Reference to a journal publication:
[1] H. Ulbrich, B. Fiebich, G. Dannhardt, Eur. J. Med. Chem. 37 (2002)
953?59.
Reference to a book:
[2] C. Melchiorre, M. Giannella (Eds.), Highlights in Receptor Chemistry,
Elsevier, Amsterdam, 1984.
Reference to a chapter in an edited book:
[3] J.P. Buyniski, R.L. Cavanagh, A.W. Pircio, A.A. Algieri, R.R. Crenshaw,
in: C. Melchiorre, M. Giannella (Eds.), Highlights in Receptor Chemistry,
Elsevier, Amsterdam, 1984, pp. 195?15.
Figure legends, tables, figures, schemes: Present these, in this order, at the
end of the article. They are described in more detail below. High-resolution
graphics files must always be provided separate from the main text file (see
Preparation of illustrations).
Captions: Ensure that each illustration has a caption. Supply captions on a
separate sheet, not attached to the figure. Acaption should comprise a brief title
(not on the figure itself) and a description of the illustration. Keep text in the
illustrations themselves to a minimum but explain all symbols and abbreviations
used.
Tables: Number tables consecutively in accordance with their appearance in
the text. Place footnotes to tables below the table body and indicate them with
superscript lowercase letters. Avoid vertical rules. Be sparing in the use of
tables and ensure that the data presented in tables do not duplicate results
described elsewhere in the article.
Figures and Schemes: Figures and Schemes should be consecutively numbered
with Arabic numerals, according to their order of appearance in the main text.
Any lettering (symbols, numbers, etc.) in the illustrations should be used in a
consistent way and be of consistent size. Mark the appropriate position of a
figure/scheme in the text.
Text graphics: Present incidental graphics not suitable for mention as figures,
plates or schemes at the end of the article and number them ‘Graphic 1? etc.
Their precise position in the text can then be defined similarly (both on the
manuscript and in the file). Ensure that high-resolution graphics files are provided,
even if the graphic appears as part of your normal wordprocessed text file.
5. Illustrations
5.1 Preparation of electronic illustrations
Submitting your artwork in an electronic format helps us to produce your work
to the best possible standards, ensuring accuracy, clarity and a high level of
detail.
General points
Always supply high-quality printouts of your artwork, in case conversion of
the electronic artwork is problematic.
Make sure you use uniform lettering and sizing of your original artwork.
Only use the following fonts in your illustrations: Arial, Courier, Helvetica,
Times, Symbol.
Number the illustrations according to their sequence in the text.
Use a logical naming convention for your artwork files, and supply a
separate listing of the files and the software used.
Provide all illustrations as separate files and as hardcopy printouts on
separate sheets.
Provide captions to illustrations separately.
Produce images near to the desired size of the printed version or larger. If
providing larger than intended publication size, please scale text such that it
will remain readable after reduction.
To help authors provide actual size graphics, it is suggested that the following
settings be used with CSC ChemDrawTM and ISIS DrawTM: font 10 pt
Helvetica, chain angle 120? bond spacing 18 % of length, fixed length 14.4 pt
(0.508 cm), bold width 2.0 pt (0.071 cm), line width 0.6 pt (0.021 cm), margin
width 1.6 pt (0.056 cm), and hash spacing 2.5 pt (0.088 cm). Compound numbers
should be in boldface. With these settings, to ensure a proper size, the
graphic must be printed at 70 %. In order to accurately design schematics to
print out at the proper width with the reduction, the original drawing cannot
exceed a column width of 12.0 cm (for single column) and 25.0 cm (for double
column). To produce a double column width landscape mode will need to be
used. A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information
are given here.
Formats
Regardless of the application used, when your electronic artwork is finalised,
please “save as?or convert the images to one of the following formats (Note
the resolution requirements for line drawings, halftones, and line/halftone combinations
given below.):
EPS: Vector drawings. Embed the font or save the text as “graphics?
TIFF: Colour or greyscale photographs (halftones): always use a minimum of
300 dpi. For colour images always use CMYK.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (colour or greyscale): a minimum
of 500 dpi is required.
DOC, XLS or PPT: If your electronic artwork is created in any of these
Microsoft Office applications please supply “as is?
Please do not:
Supply embedded graphics in your wordprocessor (spreadsheet, presentation)
document;
Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG);
the resolution is too low;
Supply files that are too low in resolution;
Submit graphics that are disproportionately large for the content.
5.2 Preparation of non-electronic illustrations
Provide all illustrations as high-quality printouts, suitable for reproduction
(which may include reduction) without retouching. Submit colour illustrations
as original photographs, high-quality computer prints or transparencies, close
to the size expected in publication, or as 35 mm slides. Number illustrations
consecutively in the order in which they are referred to in the text. They should
accompany the manuscript, but should not be included within the text. Clearly
mark all illustrations on the back (or ?in case of line drawings ?on the lower
front side) with the figure number and the author’s name and, in cases of ambiguity,
the correct orientation.
Line drawings
Supply high-quality printouts on white paper produced with black ink. The lettering
and symbols, as well as other details, should have proportionate dimensions, so
as not to become illegible or unclear after possible reduction; in general, the
figures should be designed for a reduction factor of two to three. The degree of
reduction will be determined by the Publisher. Illustrations will not be enlarged.
Consider the page format of the journal when designing the illustrations.
Photocopies are not suitable for reproduction. Do not use any type of shading
on computer-generated illustrations.
Photographs (halftones)
Please supply original photographs for reproduction, printed on glossy paper,
very sharp and with good contrast. Remove non-essential areas of a photograph.
Do not mount photographs unless they form part of a composite figure.
Where necessary, insert a scale bar in the illustration (not below it), as opposed
to giving a magnification factor in the legend.
Note that photocopies of photographs are not acceptable.
5.3. Colour figure charges
Colour in print: Colour figures may be printed in the journal at no charge to the
author, provided that the Editor considers the colour necessary to convey scientific
information. In all other instances, costs of colour reproduction will be
entirely charged to the authors.
Colour on the Web: as a new feature any figure can appear free of charge in
colour in the web version of your article (e.g. on ScienceDirect), regardless of
whether or not this is reproduced in colour in the printed version. Please note
that if you do not opt for colour in print, you should submit relevant figures in
both colour (for the web) and black and white (for print).
5.4. Supplementary material
Elsevier accepts electronic supplementary material to support and enhance
your scientific research. Supplementary files offer the author additional
possibilities to publish supporting applications, movies, animation sequences,
high-resolution images, background datasets, sound clips, and more.
Supplementary files supplied will be published online alongside the electronic
version of your article in Elsevier web products, including ScienceDirect
http://www.sciencedirect.com. To ensure that your submitted material is
directly usable, please provide data in one of our recommended file formats.
Supplementary data must be saved in files separate from those for the
manuscript and figures, and all file names must be supplied. Supplementary
files should either be referred to from within the text of your manuscript in the
same way as for figures or tables, or their presence be indicated by adding a
paragraph entitled “Supplementary data?at the end of the manuscript, detailing
which data are supplied. In addition, authors should also provide a concise and
descriptive caption for each file.
When supplying supplementary data, authors must state whether the data files
are either (i) for online publication or (ii) to be used as an aid for the refereeing
of the paper only. All supplementary data will be subject to peer review.
For more detailed instructions, please visit http://www.elsevier.com/artwork
instructions
6. Proofs
One set of page proofs in PDF format will be sent by e-mail to the corresponding
author and should be returned with corrections as quickly as possible,
normally within 48 hours of receipt of the proofs. Should there be no
corrections, please confirm this. The Publisher reserves the right to proceed
with publication if corrections are not communicated.
Elsevier will do everything possible to get your article corrected and published
as quickly and accurately as possible. In order to do this we need your help.
When you receive the (PDF) proof of your article for correction, it is important
to ensure that all of your corrections are sent back to us in one communication.
Subsequent corrections will not be possible, so please ensure your first sending
is complete. Note that this does not mean you have any less time to make your
corrections, just that only one set of corrections will be accepted.
7. Reprints
The corresponding author, at no cost, will be provided with a PDF file of the
article via e-mail or, alternatively, with twenty-five free paper offprints. The
PDF file is a watermarked version of the published article and includes a cover
sheet with the journal cover image and a disclaimer outlining the terms and
conditions of use.
8. Author enquiries
Visit the http://www.elsevier.com/trackarticle for the facility to track accepted
articles and set up e-mail alerts to inform you of when an article’s status has
changed.
Contact details for questions arising after acceptance of an article, especially
those relating to proofs, are provided after registration of an article for
publication.
April 2007
Instructions to Authors
instructions for author.pdf
Editorial Board
Editorial Board
Editors:
O. Lafont
Secrétariat EJMC, Facult?de Pharmacie, Universit?de Paris-Sud, 5, rue Jean-Baptiste-Clément, F-92296 Châtenay-Malabry Cedex, France, Tel: +33-1-4683.5684, Fax: +33-1-4683.5323, Email: eur.jmedchem@cep.u-psud.fr
S. Guccione
Dipartimento di Scienze Farmaceutiche, Universit?degli Studi di Catania, Viale Andrea Doria 6 - Ed. 12, Citt?Universitaria, I-95125 Catania, Italy, Tel: +39-95-738.4020, Fax: +39-95-504.572, Email: guccione@unict.it
A. Monge-Vega
Departamento Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Navarra, E-31080 Pamplona, Spain, Tel: +34-948-425.653, Fax: +34-948-425.652, Email: cifa@unav.es
Honorary Editor-in-Chief
C. Combet-Farnoux
Facult?de Pharmacie (Paris-Sud), Châtenay-Malabry, France
Editorial Advisory Board:
P.R. Andrews
Australia
J.R. Chrétien
France
J.C. Dearden
UK
F.G. De las Heras
Spain
F. Durant
Belgium
J. Elguero
Spain
G. Folkers
Switzerland
C.R. Ganellin
UK
S. Goldmann
Germany
F. Gualtieri
Italy
U. Hacksell
Sweden
H.D. Höltje
Germany
P. Krogsgaard-Larsen
Denmark
B. Macchia
Italy
Y.C. Martin
USA
W.G. Richards
UK
W. Schunack
Germany
H. Tanida
Japan
A. Tartar
France
B. Testa
Switzerland
H. Timmerman
The Netherlands
J. Tollenaere
Belgium
J.G. Topliss
Turkey
V. Tortorella
Italy
H. van de Waterbeemd
UK
H. Vanden Bossche
Belgium
C.G. Wermuth
France
R.N. Young
Canada
|
刊名字顺( Alphabetical List of Journals):
返回页首 